Bromocriptine Markedly Suppresses Levodopa-Induced Abnormal Increase of Dopamine Turnover in the Parkinsonian Striatum
Authors:
- 1 June 2000
- journal article
- Published by Springer Nature in Neurochemical Research
- Vol. 25 (6) , 755-758
Abstract
Bromocriptine, a dopamine agonist, is commonly used in combination with levodopa for the treatment of Parkinson's disease (PD). To investigate the theoretical basis of such combination therapy, we...Keywords
This publication has 20 references indexed in Scilit:
- Significant Behavioral Recovery in Parkinson's Disease Model by Direct Intracerebral Gene Transfer Using Continuous Injection of a Plasmid DNA–Liposome ComplexHuman Gene Therapy, 1998
- Early institution of bromocriptine in Parkinson's disease inhibits the emergence of levodopa-associated motor side effects. Long-term results of the PRADO studyJournal of Neural Transmission, 1996
- Toxic effects of L-DOPA on mesencephalic cell cultures: protection with antioxidantsBrain Research, 1995
- Induction of apoptosis in catecholaminergic PC12 cells by L-DOPA. Implications for the treatment of Parkinson's disease.Journal of Clinical Investigation, 1995
- The Sydney Multicentre Study of Parkinson's disease: a randomised, prospective five year study comparing low dose bromocriptine with low dose levodopa-carbidopa.Journal of Neurology, Neurosurgery & Psychiatry, 1994
- Parkinson's disease.Journal of Neurology, Neurosurgery & Psychiatry, 1994
- Levodopa and Dopamine Agonists in the Treatment of Parkinson’s Disease: Advantages and DisadvantagesEuropean Neurology, 1994
- Long-Term Double Masked Trial of Early Treatment with L-Dopa plus Bromocriptine versus L-Dopa alone in Parkinson’s DiseaseEuropean Neurology, 1990
- A randomised controlled study of bromocriptine versus levodopa in previously untreated Parkinsonian patients: a 3 year follow-up.Journal of Neurology, Neurosurgery & Psychiatry, 1989
- The “On–Off” Phenomenon in Parkinson’s DiseaseNew England Journal of Medicine, 1984